EGFR and neoplasm: Besides, immunohistochemistry performed on tumor samples from 19 patients showed EGFR tumor positivity in pre-therapy lesions in 16% of patients (Supplementary Table 4), suggesting its potential targeting independently from BRAFi-treatment or in CM that are intrinsically resistant to BRAFi and that are marked by EGFR upregulation (36).